Cyclerion Therapeutics (NASDAQ:CYCN) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Cyclerion Therapeutics (NASDAQ:CYCN) posted its quarterly earnings results on Monday. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.19, FiscalAI reports. Cyclerion Therapeutics had a negative net margin of 77.02% and a negative return on equity of 24.61%. The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.10 million.

Cyclerion Therapeutics Stock Down 4.0%

NASDAQ CYCN opened at $1.45 on Tuesday. The company has a market cap of $5.68 million, a PE ratio of -1.93 and a beta of 0.94. Cyclerion Therapeutics has a 52 week low of $1.03 and a 52 week high of $3.79. The firm’s 50-day simple moving average is $1.38 and its two-hundred day simple moving average is $1.69.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the third quarter, according to its most recent filing with the SEC. The fund acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.